Ignite Creation Date:
2024-05-05 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00461344
Status:
TERMINATED
Last Update Posted:
2008-04-03
First Post:
2007-04-17
Brief Title:
Docetaxel Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Multicenter Open Label Phase II Trial Evaluating Docetaxel Anthracycline x 4 Cycles Followed by Docetaxel Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Relapsed 12 Months From Completion of NeoadjuvantAdjuvant Taxotere- Based Chemotherapy
Status:
TERMINATED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
due to slow recruitment of patients
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary To determine the pathological remission following the chemotherapy combination docetaxel and doxorubicin in large breast cancer
Secondary
Clinical response rate
To investigate the safety of docetaxel doxorubicin combination in the treatment for neoadjuvant chemotherapy of breast cancer
Type of surgery radicalconservative
Secondary
Clinical response rate
To investigate the safety of docetaxel doxorubicin combination in the treatment for neoadjuvant chemotherapy of breast cancer
Type of surgery radicalconservative
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None